Aptinyx’s investigational therapy NYX-458 failed to be superior to a placebo at improving cognitive function in people with dementia due to Parkinson’s disease or Lewy body dementia in a Phase 2 clinical trial. These findings prompted the company to stop development work on NYX-458. “We are very disappointed…

A first patient with Parkinson’s disease has been dosed with UB-312, Vaxxinity’s experimental vaccine therapy targeting alpha-synuclein, after treatment safety and tolerability was seen in healthy volunteers in a clinical trial. This marks the beginning of Part B in the Phase 1 trial (NCT04075318), which is enrolling up…

I never realized the benefits of music until I was diagnosed with Parkinson’s disease. Early in my diagnosis, I met Alexander Pantelyat, MD, co-director of the Johns Hopkins Center for Music and Medicine, who introduced me to both music and dance. Together with boxing and other exercises,…

Previous falls, hallucinations, and cognitive problems are among the factors that predict a risk of recurrent falls in elderly people with parkinsonian gait, a study suggests. The study, “Parkinsonian gait in elderly people: Significance of the threshold value of two and more falls per year,” was published in the…